Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of the Use of Antiretroviral Regimens Containing Raltegravir for Prophylaxis of Mother-to-child-transmission of HIV Infection in Pregnant Women Presenting With Detectable Viral Load After 32 Weeks of Gestation: a Pilot Study

Trial Profile

Evaluation of the Use of Antiretroviral Regimens Containing Raltegravir for Prophylaxis of Mother-to-child-transmission of HIV Infection in Pregnant Women Presenting With Detectable Viral Load After 32 Weeks of Gestation: a Pilot Study

Completed
Phase of Trial: Phase II/III

Latest Information Update: 11 Feb 2019

At a glance

  • Drugs Raltegravir (Primary) ; Lamivudine/zidovudine; Lopinavir/ritonavir
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Apr 2018 Primary endpoint (HIV Viral load at delivery [Time Frame: 2 months ]) has been met, according to results published in the HIV Clinical Trials.
    • 09 Apr 2018 Status changed from active, no longer recruiting to completed,as per results published in the HIV Clinical Trials.
    • 09 Apr 2018 Results comparing safety and efficacy of raltegravir and lopinavir/ritonavir for the prevention of mother to child transmission in pregnant women with HIV 1 infections published in the HIV Clinical Trials
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top